NASDAQ:PRAH - PRA Health Sciences Stock Price, News, & Analysis

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

PRA Health Sciences Inc (NASDAQ:PRAH) released its quarterly earnings data on Wednesday, February, 27th. The medical research company reported $1.21 EPS for the quarter, topping analysts' consensus estimates of $1.18 by $0.03. The medical research company had revenue of $729.65 million for the quarter, compared to the consensus estimate of $750.67 million. PRA Health Sciences had a net margin of 5.50% and a return on equity of 26.87%. View PRA Health Sciences' Earnings History.

PRA Health Sciences is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for PRA Health Sciences.

PRA Health Sciences issued an update on its FY19 earnings guidance on Wednesday, May, 1st. The company provided EPS guidance of $4.93-$5.08 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.02. The company issued revenue guidance of $3.09-$3.20 billion, compared to the consensus revenue estimate of $3.13 billion.

9 analysts have issued 1 year target prices for PRA Health Sciences' stock. Their predictions range from $100.00 to $122.00. On average, they expect PRA Health Sciences' stock price to reach $114.25 in the next twelve months. This suggests a possible upside of 30.4% from the stock's current price. View Analyst Price Targets for PRA Health Sciences.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 4 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PRA Health Sciences.

Press coverage about PRAH stock has trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PRA Health Sciences earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned news stories about the medical research company a news buzz of 7.0 out of 10, meaning that recent press coverage is likely to have an impact on the stock's share price in the immediate future.

Some companies that are related to PRA Health Sciences include Incyte (INCY), EXACT Sciences (EXAS), Icon (ICLR), Charles River Laboratories Intl. (CRL), Exelixis (EXEL), Syneos Health (SYNH), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Geovax Labs (GOVX), Sorrento Therapeutics (SRNE), Eloxx Pharmaceuticals (ELOX), STARPHARMA HOLD/S (SPHRY), Anavex Life Sciences (AVXL) and Pieris Pharmaceuticals (PIRS).

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include Mattel (MAT), Ultra Clean (UCTT), General Electric (GE), Twitter (TWTR), US Foods (USFD), American National BankShares (AMNB), Enterprise Bancorp (EBTC), New York Times (NYT), Alibaba Group (BABA) and General Motors (GM).

(PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at a price of $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

PRA Health Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (9.46%), Wellington Management Group LLP (4.40%), FMR LLC (4.39%), AQR Capital Management LLC (2.78%), Frontier Capital Management Co. LLC (1.37%) and Eagle Asset Management Inc. (1.35%). Company insiders that own PRA Health Sciences stock include Colin Shannon, David W Dockhorn, Linda Baddour, Matthew P Young and Pra Investors LP Kkr. View Institutional Ownership Trends for PRA Health Sciences.

PRAH stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Eagle Asset Management Inc., First Trust Advisors LP, Carillon Tower Advisers Inc., Goldman Sachs Group Inc., Swedbank, Pendal Group Ltd and Wellington Management Group LLP. View Insider Buying and Selling for PRA Health Sciences.

PRAH stock was acquired by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, FMR LLC, Strs Ohio, Virginia Retirement Systems ET AL, Voya Investment Management LLC, Natixis, Morgan Stanley and Loomis Sayles & Co. L P. View Insider Buying and Selling for PRA Health Sciences.

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of PRAH stock can currently be purchased for approximately $87.64.

PRA Health Sciences has a market capitalization of $5.75 billion and generates $2.87 billion in revenue each year. The medical research company earns $153.90 million in net income (profit) each year or $3.93 on an earnings per share basis. PRA Health Sciences employs 16,400 workers across the globe.

The official website for PRA Health Sciences is http://www.prahs.com/.

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]